Weight-loss drug semaglutide does not slow Alzheimer's disease, two clinical trials find

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the first large Phase III randomized controlled trials on the topic published in The Lancet.